Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancer
Translational Oncology · 2025-08 · 58 · 102432
DOI: 10.1016/j.tranon.2025.102432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2025-08. Verfasst von Mudassier Ahmad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immunology, Department of Medicine and Oncology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMHD NIH HHS, University of Texas System, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Pancreatic cancer (PanCa) is projected to become the second major cause of cancer-related mortality by 2030. The current diagnostic and treatment strategies offer only marginal benefits in overall survival. This highlights the need to discover new biomarkers and targets for the treatment of PanCa. Dysregulated mitochondrial ribosome biogenesis occurs in PanCa and can be utilized as a potential biomarker and molecular target for its management. In this study, we established MRPL3 (Mitochondrial Ribosomal Protein L3) as a potential biomarker and its role in expression of ETC (Electron Transport Chain) components. We employed an integrated approach combining the in silico and experimental validation. Our findings demonstrate that the expression of MRPL3 is upregulated during PanCa in ductal adenocarcinoma and other single cell populations of pancreas. Amongst various grades, the highest expression of MRPL3 was observed in grade 1 human PanCa tumors. MRPL3 is involved in the growth of PanCa cells and the targeted knock-down of MRPL3 leads to decrease in the expression of ETC components. Moreover, in silico analysis identified that MRPL3 undergoes alternative splicing that gives rise to six coding and four non-coding variants. The MRPL3-001 isoform arising from ENSG00000114686.8 variant was found to be the most abundant in PanCa. Pathway enrichment analysis showed that MRPL3 is positively associated with cell growth and proliferation while negatively associated with cell lineage commitment and differentiation. These results represent MRPL3 as a promising early biomarker and molecular target for PanCa which warrant further investigation for its clinical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Immunology, Department of Medicine and Oncology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA; South Texas Center of Excellence for Cancer Research, School of Medi…
Förderung
- NIMHD NIH HHS
- University of Texas System
- National Institute of General Medical Sciences
- The University of Texas Rio Grande Valley, McAllen, TX
- Yale School of Management
- Cancer Prevention and Research Institute of Texas
- University of Texas Rio Grande Valley
- National Institutes of Health
Zitieren
APA
Ahmad, M., Alvi, S. S., Dhasmana, A., Benavidez, J., Yallapu, M. M., Kim, D. J., Chauhan, S. C., & Hafeez, B. B. (2025). Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancer. Translational Oncology, 58, 102432. https://doi.org/10.1016/j.tranon.2025.102432
Vancouver
Ahmad M, Alvi SS, Dhasmana A, Benavidez J, Yallapu MM, Kim DJ, et al. Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancer. Translational Oncology. 2025;58:102432. doi:10.1016/j.tranon.2025.102432
BibTeX
@article{Ahmad2025,
author = {Ahmad, Mudassier and Alvi, Sahir Sultan and Dhasmana, Anupam and Benavidez, Jasmine and Yallapu, Murali M and Kim, Dae Joon and Chauhan, Subhash C and Hafeez, Bilal Bin},
title = {Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancer},
journal = {Translational Oncology},
year = {2025},
volume = {58},
pages = {102432},
doi = {10.1016/j.tranon.2025.102432}
}
EUVIMED